Table 1.

Patient characteristics and baseline demographics for B2207 and PANORAMA-1 studies

Demographic or clinical characteristics	B2207 (dose-expansion phase)	PANORAMA-1 (Japan subset)
	PAN + BTZ + Dex	PAN + BTZ + Dex
	N = 15	N = 18
Median age in years (range)	62 (48–71)	63.5 (41–75)
ECOG PS
0 n (%)	12 (80 %)	13 (72.2 %)
1 n (%)	3 (20 %)	5 (27.8 %)
Prior therapies median (range)	2 (1–7)	2 (1–3)
Prior therapy
Prior BTZ, n (%)	11 (73.3 %)	9 (50 %)
Refractory to BTZ, n (%)	4 (26.7 %)	NA
Prior lenalidomide, n (%)	7 (46.7 %)	2 (11.1 %)
Prior thalidomide, n (%)	5 (33.3 %)	3 (16.7 %)
Prior melphalan, n (%)	1 (6.7 %)	16 (88.9 %)
Prior ASCT, n (%)	14 (93.3 %)	NA

ASCT autologous stem cell transplant, PAN panobinostat, BTZ bortezomib, Dex dexamethasone, ECOG PS Eastern Cooperative Oncology Group Performance Status score